Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01709149 · ClinicalTrials.gov registry record · Phase 2

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Cytokinetics.

Completed
Registry status
Phase 2
Development phase
711
Enrollment target
20
Study locations

NCT01709149 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Cytokinetics. The registered enrollment target is 711 participants, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01709149, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Cytokinetics.

COMPLETED
Registry status
Phase 2
Development phase
711 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).

Conditions Studied

Amyotrophic Lateral Sclerosis

Interventions

  • DRUG Riluzole
  • DRUG CK-2017357
  • OTHER Placebo tablets

Study Locations (20)

California

  • University of California, San Diego - La Jolla
  • UC Irvine ALS & Neuromuscular Center - Orange
  • Coordinated Clinical Research - San Diego
  • California Pacific Medical Center Forbes Norris MDA/ALS Research Center - San Francisco

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Hospital - Detroit
  • St Mary's Healthcare - Grand Rapids

Georgia

  • Emory University, School of Medicine - Atlanta
  • Georgia Health Sciences University - Augusta

Massachusetts

  • Massachusetts General Hospital - Boston
  • University of Massachusetts Medical School - Worcester

Arizona

  • Barrow Neurology - Phoenix

Connecticut

  • Hospital for Special Care - New Britain

District of Columbia

  • The George Washington University - Washington D.C.

Florida

  • Mayo Clinic Florida Department of Neurology - Jacksonville

Trial Details

FieldValue
Enrollment Target 711 participants
Start Date 2012-10
Est. Completion 2014-03
Phase Phase 2

Sponsor

Cytokinetics

31 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01709149

The ClinicalTrials.gov registry entry for NCT01709149 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 711 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 891-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (20% lower). The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Riluzole is the first listed.

NCT01709149 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Georgia.

Frequently Asked Questions

What is clinical trial NCT01709149 about?

NCT01709149 is a clinical study titled "Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)". The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).

What is the current status of trial NCT01709149?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 711 participants. The study started on 2012-10. Estimated completion is 2014-03.

What conditions does trial NCT01709149 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

What interventions are being tested in trial NCT01709149?

The interventions under investigation include: Riluzole (DRUG), CK-2017357 (DRUG), Placebo tablets (OTHER).

Who is sponsoring clinical trial NCT01709149?

This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01709149 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Amyotrophic Lateral Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.